T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures.
about
Human homologue of murine tumor rejection antigen gp96: 5'-regulatory and coding regions and relationship to stress-induced proteinsA new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomasHuman gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytesTumor neoantigens: building a framework for personalized cancer immunotherapyFrom mice to humans: developments in cancer immunoeditingA p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanomaAn efficient strategy to induce and maintain in vitro human T cells specific for autologous non-small cell lung carcinomaProfiling the immune response in patients with breast cancer by phage-displayed cDNA libraries.Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance.A high throughput method for identifying personalized tumor-associated antigensImmunotherapy for solid tumors--a review for surgeons.Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.Bridging innate and adaptive antitumor immunity targeting glycans.Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients.Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.T-cell-directed cancer vaccines: the melanoma model.Cell-surface antigens of melanoma recognized by human monoclonal antibodiesVaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.The genealogy of SEREXThe discovery of cancer/testis antigens by autologous typing with T cell clones and the evolution of cancer vaccinesIntroduction to monoclonal antibodies.Targeted therapy for epithelial ovarian cancer.Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma.Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens.The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene.Tumor-infiltrating T lymphocytes: friends or foes?A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles.The laboratory opossum (Monodelphis domestica) as a natural mammalian model for human cancer researchProfiling cancer testis antigens in non-small-cell lung cancer.Cytokine-based transformation of immune surveillance into tumor-promoting inflammation.Mitochondria-centric activation induced cell death of cytolytic T lymphocytes and its implications for cancer immunotherapy.T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients.Benefits of a continuous therapy for cancer patients with a novel adoptive cell therapy by cascade priming (CAPRI).The delicate balance of melanoma immunotherapy.How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances.
P2860
Q24557556-D18ADAD1-3B10-431F-B2D9-CBDA7443244DQ24679739-F0DF7DB3-E236-4325-BB05-3560FBF6D812Q24680097-0EC3B798-F460-4860-A096-C5102FB6B4C3Q28082704-14DFEB78-4B98-42C4-BD12-2F3B2B875387Q28088304-B1C66E2E-5AB4-43E3-AF77-E3BED19C30B5Q28296086-AE9720EC-E71F-43E1-9207-3BD4706391C8Q28749871-B9C519AC-BE70-4CA0-8895-A7064E0CCC90Q30657549-0CBF467E-1101-49DD-B638-FC9B629ADDDEQ32142930-6923B319-17BF-449A-843A-58447800321EQ33551458-B03E93ED-B4BD-42D2-989F-1DD2CD856668Q33658767-2CAC1558-B20F-4F2E-B8AC-339616BCE9FBQ33709232-6EC65804-FFCB-43D1-9DD4-A731B3DC2F09Q33850807-517AA99C-2B5E-42D9-A5BF-5B4D895C0207Q33960021-14EA356A-4DDD-4552-B4FF-A755037E2DDAQ34093600-F2A07897-5E73-4C95-B14D-1D6AC33C0668Q34353878-53DFBAD9-40C9-4E61-818E-15F4D38D2BA4Q34452071-25749E3F-98AF-499D-BD6F-52264DAD2C59Q34614430-2C99FA72-C7EF-4AD8-BBD4-647DB0948FB2Q34619348-23A87D34-3DCB-49F2-ADD1-F7E4DFD48E01Q35693584-CBCC8150-CB64-4ED8-9228-AC9A2CBF5164Q36049980-096113DD-D383-4E76-9798-07BF524D745BQ36049990-CA0B4AB8-0CAE-46EB-8076-DA93E474D788Q36050008-4866EF43-E17A-4DA3-AF04-02441A7C49DAQ36158708-A36C0511-663A-4C77-A6CE-E37C29E91B45Q36355478-59DB262D-243F-4079-AE16-4918EFE39B86Q36356458-F81792D3-762A-4EC0-AAB1-0ED67549C599Q36356745-246D02CD-554F-46D4-97BC-FEC925B98AA2Q36362111-4E4C7409-29AC-4DB1-B246-A84EC9587D6FQ36365847-5AD39E84-AD9A-4ADA-AB4F-21E80708B82DQ36381918-3F2D5C3B-1B14-4A40-B36D-97DC4D4DEA32Q36400634-DE3EA283-0723-4BB4-87E0-B6A07D732D8CQ36471831-CD8CD748-C8B2-45F3-9FCB-BD4B79191A9CQ37009817-425B908E-B36A-4371-893A-FDEDA9A4F0C9Q37277266-6E40BDAC-6BBE-4188-9B96-C5D7B2BDC09DQ37287166-885FC688-4FE0-416C-8A24-D0CB558A5ACEQ37745683-C1E723FB-F6ED-4C04-B021-D590E66CA8ECQ38101679-467D7A17-7C10-4AA1-A75B-509B0975E26FQ38206816-F7D0CD6F-2307-4CDA-B965-90955314F343Q38288116-9E967A66-E7D4-4C1F-AC2D-349C1905A137Q38289426-7B539E86-40A0-4592-9669-2A3389545867
P2860
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh
1984年學術文章
@zh-hant
name
T-cell-mediated cytotoxicity a ...... n 2-dependent T-cell cultures.
@ast
T-cell-mediated cytotoxicity a ...... n 2-dependent T-cell cultures.
@en
type
label
T-cell-mediated cytotoxicity a ...... n 2-dependent T-cell cultures.
@ast
T-cell-mediated cytotoxicity a ...... n 2-dependent T-cell cultures.
@en
prefLabel
T-cell-mediated cytotoxicity a ...... n 2-dependent T-cell cultures.
@ast
T-cell-mediated cytotoxicity a ...... n 2-dependent T-cell cultures.
@en
P2093
P2860
P356
P1476
T-cell-mediated cytotoxicity a ...... n 2-dependent T-cell cultures.
@en
P2093
P2860
P304
P356
10.1073/PNAS.81.11.3511
P407
P577
1984-06-01T00:00:00Z